Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Division of Cancer Prevention Staff

Portrait of Lynn R. Sorbara, PhD

Lynn R. Sorbara, PhD

Program Director
Cancer Biomarkers Research Group
Location
Division of Cancer Prevention
National Cancer Institute
9609 Medical Center Drive, Room 5E616
Rockville, MD 20850
Phone (240) 276-7135
Fax (240) 276-7845
E-mail lynns@mail.nih.gov
  • Dr. Lynn Sorbara earned her PhD from Albert Einstein College of Medicine in 1986. Her thesis research was in the areas of the mechanism of action of the drug, Taxol, and of multidrug resistance. After postdoctoral fellowships at the Rockefeller University and the Mount Sinai College of Medicine in Manhattan, she came to the NIH as a Senior Staff Fellow in the Diabetes Branch of NIDDK. From 1996 to 2007, she was the Technical Supervisor and Clinical Staff Scientist for the Molecular Diagnostics Unit of the Laboratory of Pathology at NCI. As the Technical Supervisor, she was responsible for the development, validation, and quality assurance for all of the diagnostic tests performed in this College of American Pathologists and CLIA certified laboratory. Since 2007, she has been a Program Director for the Cancer Biomarkers Research Group in the Division of Cancer Prevention of NCI.

    In her current role, she oversees and manages cooperative agreement grants for the Biomarker Reference Laboratories and is the co-coordinator of the Lung Collaborative Group for the Early Detection Research Network. She is the lead Program Director for the Cancer Prevention R03 Small Grants Program for DCP as well as a Program Representative for the Innovative Molecular Technologies Analysis and the SBIR Programs. She has a strong interest in developing Standard Operating Procedures for biomarker discovery/validation, and diagnostic assay development. Her grant portfolio includes biomarkers for early detection of hematopoietic malignancies, lung and upper aerodigestive cancers, new technologies and diagnostics tools for cancer research.



Back to top